Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:		MEMBER'S FIRST NAME:		
	iew (e.g., chart notes or	lab data, to support th	 Attach any additional documentation e authorization request). Information 	
			☐ URGENT	
MEMBER INFORMATION	N			
LAST NAME:		FIRST NAME:		
PHONE NUMBER:		DATE OF BIRTI	DATE OF BIRTH:	
STREET ADDRESS:		-		
CITY:		STATE:	ZIP CODE:	
PATIENT INSURANCE II	NUMBER:	l		
MALE FEMALE	HEIGHT (IN/CM):	_ WEIGHT (LB/KG):	ALLERGIES:	
IF YOU ARE NOT THE PADISCLOSURE AUTHORIZE FOLLOWING LINK: PRIM	ATION FORM WITH THE THERAPEUTICS.COM	IIS REQUEST WHICH M/NOPP	I CAN BE FOUND AT THE	
AUTHORIZED REPRESE				
PRESCRIBER INFORMA	TION			
LAST NAME:		FIRST NAME:		
PRESCRIBER SPECIAL	TY:	EMAIL ADDRES	EMAIL ADDRESS:	
NPI NUMBER:		DEA NUMBER:	DEA NUMBER:	
PHONE NUMBER:		FAX NUMBER:	FAX NUMBER:	
STREET ADDRESS:				
CITY:		STATE:	ZIP CODE:	
REQUESTER (if different than prescriber):		OFFICE CONTA	OFFICE CONTACT PERSON:	
		I		
MEDICATION OR MEDIC	CAL DISPENSING INFO	RMATION		
MEDICATION NAME:				
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REF	QUANTITY:	
☐ NEW THERAPY		RENEWAL: DATE T		
Continued on post page	Y (SPECIFIC DATES):			
Continued on next page				

© 2024 Prime Therapeutics Management LLC, a Prime Therapeutics company Prime Therapeutics Management – Commercial Clients. Revision Date: 7.1.25 CAT009



MEMBER'S LAST NAME: MEMBER'S FIRST NAME:					
1. HAS THE PATIENT TRIED ANY OTHER MEDICATIONS FOR THIS CONDITION?					
YES (if yes, complete below)	NO				
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	DURATION OF THERAPY (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:			
2. LIST DIAGNOSES:		ICD-10:			
Rheumatoid arthritis(RA) Moderate to severe Atopic Derma Psoriatic Arthritis (PsA) Ulcerative Colitis(UC) Crohn's Disease(CD) Ankylosing Spondylitis Non-radiographic Axial Spondyla Atopic Dermatitis Giant Cell Arteritis	• •				
Other diagnosis:	lCD-10 Code(s):				
3. REQUIRED CLINICAL INFORMATION: PLEASE PROVIDE ALL RELEVANT CLINICAL INFORMATION TO SUPPORT A PRIOR AUTHORIZATION.					
Is patient going to be using drug	in combination with a clinical trial?	? ☐ Yes ☐ No			
Will the patient use drug in combination with another biologic response modifier or immunomodulatory agent? Yes No Has the patient tried and had an inadequate response to a three month trial of the biosimilar for Humira- adalimumab-aacf? Yes No Please submit documentation.					
Does patient have a absolute contraindication to the biosimilar for Humira- adalimumab-aacf? ☐ Yes ☐ No Please submit documentation.					
Has the patient tried and had an inadequate response to a trial of the <u>biosimilar</u> for Actemra, Tyenne(tocilizumab-aazg)? □ Yes □ No Please submit documentation.					
Does patient have a absolute contraindication to the biosimilar for Actemra, Tyenne(tocilizumabazg)? ☐ Yes ☐ No Please submit documentation.					
Has the patient tried and had an inadequate response to a 4- month trial of the <u>biosimilar</u> for Stelara- Otulfi(ustekinumb-aauz)? □ Yes □ No Please submit documentation.					
Does patient have a absolute con ☐ Yes ☐ No Please submit docu	traindication to the biosimilar for mentation.	Stelara- <u>Otulfi(ustekinumb-aauz</u>)?			





MEMBER'S LAST NAME: MEMBER'S FIRST NAME:
For diagnosis of Rheumatoid Arthritis only:
Is the prescriber a rheumatologist? □ Yes □ No
Does the patient have a diagnosis of moderately to severely active rheumatoid arthritis? \hdots Yes \hdots No
Has the patient had a trial of methotrexate or another oral non-biologic disease modifying anti- rheumatic agent (DMARD) such as Imuran, Ridaura, Plaquenil, sulfasalazine or Arava? No Please submit documentation with dates of service.
Does patient have chronic alcohol abuse/alcoholism, chronic liver disease such as chronic hepatitis, fatty liver, nonalcoholic steatohepatitis/NASH, elevated liver enzymes) (Please provide documentation.)? □ Yes □ No Please submit documentation.
For renewal only: Does the patient continue to have a positive clinical response and remission of disease maintained with continued use of the medication? Yes No Please submit chart documentation.
Will the patient use drug in combination with another biologic or immunomodulatory agent? $\ \square$ Yes $\ \square$ No
Is the prescriber a rheumatologist? □ Yes □ No
For diagnosis of Atopic Dermatitis only:
Is the prescriber a dermatologist or allergist? □ Yes □ No
Has the patient had the diagnosis of atopic dermatitis for at least 12 months? $\ \square$ Yes $\ \square$ No *Please submit documentation.
Does the patient have atopic dermatitis on at least 10% or more of their body surface area? — Yes — No *Please submit documentation.
Has the patient tried at least two different topical steroids? $\ \square$ Yes $\ \square$ No *Please submit documentation.
If patient has not had at least 2 different topical steroids, has the patient tried at least one topical steroid AND one topical calcineurin inhibitor (tacrolimus or pimecrolimus)? — Yes — No *Please submit documentation.
If patient has not had at least 2 different topical steroids, has the patient tried at least one topical steroid AND Eucrisa(crisaborole)? □ Yes □ No *Please submit documentation.



MEMBER'S LAST NAME: MEMBER'S FIRST NAME:
If patient has not had at least 2 different topical steroids, has the patient tried at least one topical steroid AND Zoryve(roflumilast)? Yes No *Please submit documentation.
If patient has not had at least 2 different topical steroids, has the patient tried at least one topical steroid AND Vtama(tapinarof)? □ Yes □ No *Please submit documentation.
Has patient tried and failed a 3-month trial of Dupixent(dupilumab)? ☐ Yes ☐ No *Please submit documentation.
Has patient tried and failed a 3-month trial of Adbry(tralokinumab-ldrm)? \square Yes \square No *Please submit documentation.
Has patient tried and failed a 3-month trial of Cibinqo(abrocitinib)? □ Yes □ No *Please submit documentation.
Will RinvoqER(upadacitinib) be used in combination with Cibinqo(abrocitinib), Olumiant(baracitinib), Opzelura(ruxolitinib), Dupixent(dupilumab), Adbry(tralokinumab), Xolair(omalizumab), Nucala(mepolizumab) or Fasenra(benralizumab? Yes No
For renewal only: Does the patient continue to have a positive clinical response and remission of disease maintained with continued use of the medication? Yes No Please submit chart documentation.
Is the patient currently being treated with another biologic or immunomodulatory agent? $\ \ \Box$ Yes $\ \ \Box$ No
Is RinvoqER(upadacitinib) being used in combination with Cibinqo(abrocitinib), Olumiant(baracitinib), Opzelura(ruxolitinib), Dupixent(dupilumab), Adbry(tralokinumab), Xolair(omalizumab), Nucala(mepolizumab) or Fasenra(benralizumab? □ Yes □ No
Is the prescriber a dermatologist or allergist? □ Yes □ No
For diagnosis of <u>Psoriatic Arthritis</u> only:
Is the prescriber a rheumatologist or dermatologist? □ Yes □ No
Does the patient have documented moderately to severely active disease? No Please submit documentation
Has the patient had a trial and failed previous therapy with oral disease modifying anti-rheumatic agents (DMARDs, e.g., methotrexate, sulfasalazine (Azulfidine), leflunamide (Arava), or cyclosporine)? No Please submit documentation with dates of service.





MEMBER'S LAST NAME: MEMBER'S FIRST NAME:
For renewal only: Does the patient continue to have a positive clinical response and remission of disease maintained with continued use of the medication? Yes No Please submit chart documentation.
Is the patient currently being treated with another biologic or immunomodulatory agent? $\ \square$ Yes $\ \square$ No
Is the prescriber a rheumatologist or dermatologist? □ Yes □ No
For diagnosis of <u>Ulcerative Colitis and Crohn's Disease</u> Only: Is prescriber a gastroenterologist? □ Yes □ No Has patient tried and failed at least one of the following three therapies: corticosteroids, azathioprine, and/or 6-mercaptopurine? □ Yes □ No
For renewal only: Does the patient continue to have a positive clinical response and remission of disease maintained with continued use of the medication? Yes No Please submit chart documentation.
Is the patient currently being treated with another biologic or immunomodulatory agent? $\ \ \Box$ Yes $\ \ \Box$ No
Is the prescriber a rheumatologist or gastroenterologist? □ Yes □ No
For diagnosis of Ankylosing Spondylitis only:
Is the prescriber a rheumatologist? □ Yes □ No
Does the patient have documented active disease? Yes No Please submit documentation
Has the patient had a trial and failed previous therapy with at least two (2) non-steroidal anti- inflammatory agents (NSAIDS), unless use is contraindicated? ☐ Yes ☐ No Please submit documentation with dates of service.
For renewal only: Does the patient continue to have a positive clinical response and remission of disease maintained with continued use of the medication? Yes No Please submit chart documentation.
Is the patient currently being treated with another biologic or immunomodulatory agent? $\ \ \Box$ Yes $\ \ \Box$ No
Is the prescriber a rheumatologist? □ Yes □ No
For diagnosis of Non-radiographic Axial Spondyloarthritis only: Is the prescriber a rheumatologist? Yes No



MEMBER'S LAST NAME: MEMBER'S FIRST NAME:
Does the patient have objective signs of inflammation by presence of sacroiliitis on MRI imaging results and/or elevated C-reactive protein level? No Please submit imaging and/or lab report.
Has patient had an inadequate response to at least two different NSAIDs? \Box Yes \Box No Please submit documentation.
Has patient tried and failed or had a contraindication or intolerance to a 3-month trial with at least one biologic DMARD that is either a TNF inhibitor or an IL-17 inhibitor? ☐ Yes ☐ No Please submit documentation.
For renewal only: Does the patient continue to have a positive clinical response and remission of disease maintained with continued use of the medication? Yes No Please submit chart documentation.
Is the patient currently being treated with another biologic or immunomodulatory agent? $\ \ \Box$ Yes $\ \ \Box$ No
Is the prescriber a rheumatologist? □ Yes □ No
For Giant Cell Arteritis:
Is prescriber a rheumatologist? □ Yes □ No
Does patient have a diagnosis of Giant Cell Arteritis? Yes No Please submit chart documentation
Is patient currently on a tapering dose of corticosteroids? Yes No Will Rinvoq be used as monotherapy? Yes No
For renewal only: Does the patient continue to have a positive clinical response and remission of disease maintained with continued use of the medication? No Please submit chart documentation.
Is the patient currently being treated with another biologic or immunomodulatory agent? $\ \ \Box$ Yes $\ \ \Box$ No
Is the prescriber a rheumatologist? □ Yes □ No
Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?
Please note: Not all drugs/diagnosis are covered on all plans. This request may be denied unless all required information is received.



Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: MEMBER'S FIRST NAI	VIE:			
	<u> </u>			
ATTESTATION: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.				
Prescriber Signature or Electronic I.D. Verification:	Date:			
CONFIDENTIALITY NOTICE: The documents accompanying this transmis	sion contain confidential health			
information that is legally privileged. If you are not the intended recipient, yo				
disclosure, copying, distribution, or action taken in reliance on the contents	of these documents is strictly			
prohibited. If you have received this information in error, please notify the se	ender immediately (via return			
FAX) and arrange for the return or destruction of these documents.	, , , , , , , , , , , , , , , , , , ,			
FAX THIS FORM TO: 800-424-7640				

MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program Attn: CP-4201

P.O. Box 64811 St. Paul, MN 55164-0811 Phone: 877-228-7909

